A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in the elderly and/or poor performance status patients with recurrent or metastatic gastric cancer

Trial Profile

A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in the elderly and/or poor performance status patients with recurrent or metastatic gastric cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Capecitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
  • Indications Gastric cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 09 Apr 2013 Interim results (n=98) presented at the 104th Annual Meeting of the American Association for Cancer Research.
    • 09 Apr 2013 Status changed from recruiting to active, no longer recruiting.
    • 18 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top